Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)

Vaccine

Volumn 33, Issue 36, 2015, Pages 4398-4405

  Shimabukuro, Tom T ^a   Nguyen, Michael ^b   Martin, David ^b   DeStefano, Frank ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Adverse effect; Adverse event following immunization; Adverse reaction; Passive surveillance; Spontaneous reporting; Vaccination; Vaccine adverse event; Vaccine Adverse Event Reporting System (VAERS); Vaccine safety

Indexed keywords

INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; ORAL POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; VACCINE; WART VIRUS VACCINE;

2009 H1N1 INFLUENZA; ADVERSE DRUG REACTION; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DESCRIPTIVE RESEARCH; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ELECTRONIC MEDICAL RECORD; FEBRILE CONVULSION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HUMAN; IMMUNIZATION; INFECTION PREVENTION; INJECTION SITE REACTION; PATIENT COUNSELING; PHYSICIAN; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLIC HEALTH SERVICE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIGNAL DETECTION; TIME; TREND STUDY; VACCINE ADVERSE EVENT REPORTING SYSTEM; VIRUS STRAIN; WART VIRUS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; PATHOLOGY; POSTMARKETING SURVEILLANCE; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VACCINES;

EID: 84939569983     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.07.035     Document Type: Review

References (77)

1. Varricchio F., Iskander J., Destefano F., Ball R., Pless R., Braun M.M., et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004, 23(4):287-294.
2. Baggs J., Gee J., Lewis E., Fowler G., Benson P., Lieu T., et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics 2011, 127(Suppl 1):S45-S53.
3. Nguyen M., Ball R., Midthun K., Lieu T.A. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise. Pharmacoepidemiol Drug Saf 2012, 21(Suppl 1):291-297.
4. The Uppsala Monitoring Centre. Safer medicines, safer use of medicines, safer patients: what UMC is doing to help it happen. Available at: [accessed 5.06.15]. http://www.who-umc.org/graphics/27916.pdf.
5. Uppsala Monitoring Centre (UMC). Report from the WHO Collaborating Centre for International Drug Monitoring: activities July 2013-June 2014. Available at: [accessed 5.06.15]. http://www.who-umc.org/graphics/28368.pdf.
6. Centers for Disease Control and Prevention. Understanding the Vaccine Adverse Event Reporting System (VAERS). February 2013. Available at: [accessed 5.06.15]. http://www.cdc.gov/vaccines/hcp/patient-ed/conversations/downloads/vacsafe-vaers-color-office.pdf.
7. Council for International Organizations of Medical Sciences (CIOMS) Definition and application of terms for vaccine pharmacovigilance: report of CIOMS/WHO working group on vaccine pharmacovigilance 2012, WHO Press, World Health Organization, Geneva, Switzerland.
8. Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guideline for industry. Clinical safety data management: definitions and standards for expedited reporting. March 1995. Available at: [accessed 5.06.15]. http://www.fda.gov/downloads/Drugs/Guidances/ucm073087.pdf.
9. Council for International Organizations of Medical Sciences (CIOMS). Practical aspects of signal detection in pharmacovigilance: report of CIOMS working group VIII 2010, CIOMS, Geneva, Switzerland.
10. Marshall V., Baylor N.W. Food and Drug Administration regulation and evaluation of vaccines. Pediatrics 2011, 127(Suppl 1):S23-S30.
11. Chen R.T., Davis R.L., Rhodes P.H. Special methodological issues in pharmacoepidemiology studies of vaccine safety. Pharmacoepidemiology 2005, John Wiley & Sons, Sussex. 4th ed. B.L. Strom (Ed.).
12. Centers for Disease Control and Prevention. State school immunization requirements and vaccine exemption laws. February-March 2015. Available at: [accessed 5.06.15]. http://www.cdc.gov/phlp/docs/school-vaccinations.pdf.
13. Centers for Disease Control and Prevention. State immunization laws for healthcare workers and patients. November 2014. Available at: [accessed 5.06.15]. http://www2a.cdc.gov/vaccines/statevaccsApp/default.asp.
14. Iskander J.K., Miller E.R., Chen R.T. The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safety. Pediatr Ann 2004, 33(9):599-606.
15. Singleton J.A., Lloyd J.C., Mootrey G.T., Salive M.E., Chen R.T. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. VAERS Working Group. Vaccine 1999, 17(22):2908-2917.
16. Centers for Disease Control and Prevention Surveillance for adverse events following immunization using the Vaccine Adverse Event Reporting System (VAERS). Manual for the surveillance of vaccine-preventable diseases 2011, October, Centers for Disease Control and Prevention, Atlanta, GA.
17. Centers for Disease Control and Prevention Vaccine Adverse Event Reporting System - United States. MMWR Morb Mortal Wkly Rep 1990, 39(41):730-733.
18. Chen R.T., Rastogi S.C., Mullen J.R., Hayes S.W., Cochi S.L., Donlon J.A., et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 1994, 12(6):542-550.
19. 42 U.S. Code §§ 300aa-1 to 300aa-34. National Childhood Vaccine Injury Act (1986).
20. What can be reported to VAERS? Available at: [accessed 5.06.15]. https://vaers.hhs.gov/about/faqs.
21. U.S. Code of Federal Regulations, 21 CFR 600.80. Postmarketing reporting of adverse experiences (2014). Available at: [accessed 5.06.15]. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=600.80.
22. 42 U.S. Code § 300aa-25. Recording and Reporting of Information (1999). Available at: [accessed 5.06.15]. http://www.fda.gov/RegulatoryInformation/Legislation/ucm180189.htm.
23. VAERS Table of Reportable Events Following Vaccination. Available at: [accessed 5.06.15]. https://vaers.hhs.gov/resources/VAERS_Table_of_Reportable_Events_Following_Vaccination.pdf.
24. Cook K.M., Evans G. The National Vaccine Injury Compensation Program. Pediatrics 2011 May, 127(Suppl 1):S74-S77.
25. Vaccine Injury Table. Available at: [accessed 5.06.15]. http://www.hrsa.gov/vaccinecompensation/vaccineinjurytable.pdf.
26. Medical Dictionary for Regulatory Activities (MedDRA). Available at: [accessed 5.06.15]. http://www.meddra.org/.
27. Smith J.C. The structure, role, and procedures of the U.S. Advisory Committee on Immunization Practices (ACIP). Vaccine 2010, 28(April (Suppl 1)):A68-A75.
28. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat 1999, 53:177-190.
29. Szarfman A., Machado S.G., O'Neill R.T. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 2002, 25(6):381-392.
30. Evans S.J., Waller P.C., Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001, 10(6):483-486.
31. Ambrose C.S., Walker R.E., Connor E.M. Live attenuated influenza vaccine in children. Semin Pediatr Infect Dis 2006, 17(October (4)):206-212.
32. Kohl K.S., Bonhoeffer J., Braun M.M., Chen R.T., Duclos P., Heijbel H., et al. The Brighton Collaboration: creating a global standard for case definitions (and guidelines) for adverse events following immunization. Advances in patient safety: from research to implementation. Concepts and methodology 2005, vol 2. Agency for Healthcare Research and Quality (US), Rockville, MD.
33. Rosenthal S., Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health 1995, 85(12):1706-1709.
34. Verstraeten T., Baughman A.L., Cadwell B., Zanardi L., Haber P., Chen R.T. Enhancing vaccine safety surveillance: a capture-recapture analysis of intussusception after rotavirus vaccination. Am J Epidemiol 2001, 154(11):1006-1012.
35. Vellozzi C., Broder K.R., Haber P., Guh A., Nguyen M., Cano M., et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine 2010, 28(45):7248-7255.
36. Bakare N., Menschik D., Tiernan R., Hua W., Martin D. Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS). Vaccine 2010, 28(40):6609-6612.
37. Loughlin A.M., Marchant C.D., Adams W., Barnett E., Baxter R., Black S., et al. Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine 2012, 30(50):7253-7259.
38. VAERS data: guide to interpreting VAERS case report information. Available at: [accessed 5.06.15]. https://vaers.hhs.gov/data/index.
39. Zipprich J., Winter K., Hacker J., Xia D., Watt J., Harriman K. Measles outbreak - California, December 2014-February 2015. MMWR Morb Mortal Wkly Rep 2015, 64(February (6)):153-154.
40. Shilhavy B. Zero US measles deaths in 10 years, but over 100 measles vaccine deaths reported. Health Impact News, February 12, 2015. Available at: [accessed 5.06.15]. http://healthimpactnews.com/2015/zero-u-s-measles-deaths-in-10-years-but-over-100-measles-vaccine-deaths-reported/.
41. Huff EA. Measles vaccines kill more people than measles, CDC data proves. Global research, February 5, 2015. Available at [accessed 5.06.15]. http://www.globalresearch.ca/measles-vaccines-kill-more-people-than-measles-cdc-data-proves/5429736.
42. Moro P.L., Arana J., Cano M., Lewis P., Shimabukuro T.T. Deaths reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 1997-2013. Clin Infect Dis 2015, (May). pii: civ423.
43. Weber J.C.P. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. Advances in inflammation research 1984, vol 6:1-6. Raven Press, New York.
44. Erickson N. How closely does the CDC monitor HPV vaccine safety? January 5, 2014. Available at: [accessed 5.06.15]. http://sanevax.org/closely-cdc-monitor-hpv-vaccine-safety/.
45. Gee J., Naleway A., Shui I., Baggs J., Yin R., Li R., et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011, 29(October (46)):8279-8284.
46. Chao C., Klein N.P., Velicer C.M., Sy L.S., Slezak J.M., Takhar H., et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 2012, 271(February (2)):193-203.
47. Klein N.P., Hansen J., Chao C., Velicer C., Emery M., Slezak J., et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med 2012, 166(December (12)):1140-1148.
48. Arnheim-Dahlström L., Pasternak B., Svanström H., Sparén P., Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013, 347(October):f5906.
49. Grimaldi-Bensouda L., Guillemot D., Godeau B., Bénichou J., Lebrun-Frenay C., Papeix C., et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med 2014, 275(April (4)):398-408.
50. Scheller N.M., Pasternak B., Svanström H., Hviid A. Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism. JAMA 2014, 312(July (2)):187-188.
51. Scheller N.M., Svanström H., Pasternak B., Arnheim-Dahlström L., Sundström K., Fink K., et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA 2015, 313(January (1)):54-61.
52. Centers for Disease Control and Prevention Intussusception among recipients of rotavirus vaccine - United States, 1998-1999. MMWR Morb Mortal Wkly Rep 1999, 48(27):577-581.
53. Centers for Disease Control and Prevention Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine - United States, June-July 2005. MMWR Morb Mortal Wkly Rep 2005, 54(October (40)):1023-1025.
54. Centers for Disease Control and Prevention Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine - United States, October 2005-February 2006. MMWR Morb Mortal Wkly Rep 2006, 55(April (13)):364-366.
55. Centers for Disease Control and Prevention Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine - United States, June 2005-September 2006. MMWR Morb Mortal Wkly Rep 2006, 55(October (41)):1120-1124.
56. Braun M.M., Patriarca P.A., Ellenberg S.S. Syncope after immunization. Arch Pediatr Adolesc Med 1997, 151(March (3)):255-259.
57. Centers for Disease Control and Prevention Syncope after vaccination - United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep 2008, 57(May (17)):457-460.
58. Leroy Z., Broder K., Menschik D., Shimabukuro T., Martin D. Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system. Vaccine 2012, 30(11):2020-2023.
59. Martin D., Menschik D., Bryant-Genevier M., Ball R. Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine. Drug Saf 2013, 36(7):547-556.
60. Braun M.M., Mootrey G.T., Salive M.E., Chen R.T., Ellenberg S.S. Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS). Pediatrics 2000, 106(October (4)):E51.
61. Slade B.A., Leidel L., Vellozzi C., Woo E.J., Hua W., Sutherland A., et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009, 302(7):750-757.
62. Centers for Disease Control and Prevention Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009. MMWR Morb Mortal Wkly Rep 2009, 58(48):1351-1356.
63. Moro P.L., Broder K., Zheteyeva Y., Walton K., Rohan P., Sutherland A., et al. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009. Am J Obstet Gynecol 2011, 204(2). 146.e1-7.
64. Centers for Disease Control and Prevention Suspension of rotavirus vaccine after reports of intussusception - United States, 1999. MMWR Morb Mortal Wkly Rep 2004, 53(September (34)):786-789. Erratum in: MMWR Morb Mortal Wkly Rep 2004; 53(September (37)):879.
65. Centers for Disease Control and Prevention Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 1999, 48(November (43)):1007.
66. Tse A., Tseng H.F., Greene S.K., Vellozzi C., Lee G.M., VSD Rapid Cycle Analysis Influenza Working Group Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine 2012, 30(March (11)):2024-2031.
67. Centers for Disease Control and Prevention. Febrile seizures in children following vaccination with influenza vaccines and pneumococcal vaccines - 2010-2011 influenza season. Available at: [accessed 5.06.15]. http://www.cdc.gov/vaccinesafety/Concerns/FebrileSeizures-archived.html.
68. Shimabukuro T. The Vaccine Adverse Event Reporting System (VAERS) form Version 2.0 (proposed). Presented at the National Vaccine Advisory Committee meeting 2014.
69. Request for comment on draft Vaccine Adverse Event Reporting System (VAERS) 2.0 form 2014, November, 69853-69854. C. Department of Health and Human Services (Ed.).
70. Postmarketing safety reports for human drug and biological products; electronic submission requirements 2014, June, 33072-33092. F. Department of Health and Human Services (Ed.).
71. Draft guidance for industry on providing submissions in electronic format - postmarketing safety reports 2014, June, 33200-33201. Department of Health and Human Services, Food and Drug Administration. D. Services (Ed.).
72. Vellozzi C., Broder K.R., Haber P., Guh A., Nguyen M., Cano M., et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine 2010, 28(October (45)):7248-7255.
73. Hinrichsen V.L., Kruskal B., O'Brien M.A., Lieu T.A., Platt R. Using electronic medical records to enhance detection and reporting of vaccine adverse events. J Am Med Inform Assoc 2007, 14(November-December (6)):731-735.
74. Baker M.A., Kaelber D.C., Bar-Shain D.S., Moro P.L., Zambarano B., Mazza M., et al. Advanced clinical decision support for vaccine adverse event detection and reporting. Clin Infect Dis 2015, (June). pii: civ430.
75. Lieu T.A., Kulldorff M., Davis R.L., Lewis E.M., Weintraub E., Yih K., et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care 2007, 45(October (10 Suppl 2)):S89-S95.
76. Connolly H.M., Crary J.L., McGoon M.D., Hensrud D.D., Edwards B.S., Edwards W.D., et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997, 337(August (9)):581-588. Erratum in: N Engl J Med 1997; 337(December 24):1783.
77. Centers for Disease Control and Prevention Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997, 46(November (45)):1061-1066.